Biofrontera AG (0DOL.L)
| Previous close | 3.0618 |
| Open | 2.4270 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 2.3580 - 2.4270 |
| 52-week range | 2.3580 - 2.4270 |
| Volume | 65,511 |
| Avg. volume | N/A |
| Market cap | 105.733M |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2140 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für klinische Spezialpräparate mbH. (Medac), signed an exclusive license and supply agreement for the marketing of both Ameluz® and BF-RhodoLED® in Poland. The agreement has a term of 5 years commencing with the start of sales in Poland. Under the terms of the agreement, Medac will make an immediate one-t
- Globe Newswire
Biofrontera Inc. seeks IPO in the USA
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc. Biofrontera AG had already announced that opportunities for capital raises were being evaluated including a potential initial public offering ("IPO") of Biofrontera Inc. in the United States. The main objectives of an IPO of Biofrontera Inc. would be to raise additional capital to fund its growth of operations, to create a public market for its shares and to
- Globe Newswire
Biofrontera reports preliminary revenue for the month of June 2021
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of June 2021. The Company’s preliminary, unaudited revenue from product sales in June 2021 amounted to approximately EUR 2,626 thousand, compared to EUR 1,701 thousand in June 2020, an increase of 50%. Preliminary revenues from product sales in the US were around
